Reduced Toxicity, Myeloablative Conditioning Regimen with Busulfan, Fludarabine, Anti-Thymocyte Globulin and 400 Cgy TBI in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant for High-Risk Hematologic Malignancies
Jenna Rossoff(Lurie Children's Hospital), Sonali Chaudhury(Northwestern University), Jennifer Schneiderman(Northwestern University), David A. Jacobsohn(Children's National), Reggie Duerst(Lurie Children's Hospital), Morris Kletzel(Lurie Children's Hospital), William Tse(Lurie Children's Hospital), Soyang Kwon(Northwestern University)
Cited by 0
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|255
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248